Position in ABBV
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,005,413,024
+$231,187,990 QoQ
Shares Held
3,995,442
+12.2% QoQ
Ownership
0.226%
of shares outstanding
% of Portfolio
0.68%
of 13F equity value
Holder Rank
#50
of 4,138 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026VANGUARD ASSET MANAGEMENT, Ltd holds $9,837,794,896 across 11 Drug Manufacturers - General names. ABBV ranks #4 (10.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
18,712,920 | $3,548,343,890 | |
| 2 | LLY |
ELI LILLY & Co
|
1,556,634 | $1,867,073,674 | |
| 3 | JNJ |
Johnson & Johnson
|
4,960,069 | $1,259,708,723 | |
| 4 | ABBV |
AbbVie Inc.
This page
|
3,995,442 | $1,005,413,024 | |
| 5 | MRK |
Merck & Co., Inc.
|
5,593,255 | $718,733,267 | |
| 6 | AMGN |
Amgen Inc
|
1,219,518 | $441,611,858 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
2,816,761 | $355,869,584 | |
| 8 | PFE |
Pfizer Inc
|
12,875,264 | $310,036,357 |
All Filings in ABBV
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,005,413,024 | 3,995,442 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $774,225,034 | 3,559,819 | Shares | Defined | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||